Clinical Trial Update: Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

Phase 2 dose-determination safety and activity study of inhaled NX1011 for pulmonary arterial hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• NX1011

Snippet

Sponsor: NITROX, LLC | Conditions: Pulmonary Hypertension | Phase 2 | Status: WITHDRAWN